Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.
Faiza Fatima, Anurag Jha, Ahmed Raza et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and random-effects meta-analysis assessed the efficacy and safety of ponatinib plus blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), including newly diagnosed and relapsed/refractory disease. Across 8 studies, pooled overall survival was 84%, with 93% in newly diagnosed patients and 50% in refractory cases. The pooled complete molecular response rate was 89%, and the adverse-event rate was 17%, falling to 11% after sensitivity analysis. The authors describe the combination as promising, particularly as a frontline chemotherapy-free regimen, while calling for larger randomized trials.
Key findings
- Pooled overall survival was 84%; it was 93% in newly diagnosed patients and 50% in refractory cases.
- Overall event-free survival was 64%, rising to 86% in the newly diagnosed subgroup.
- The pooled complete molecular response rate was 89%, and hematologic response reached 93%.
- The pooled adverse-event rate was 17%, decreasing to 11% after sensitivity analysis.
Why it matters
The pooled results suggest that combining a tyrosine kinase inhibitor with blinatumomab may achieve substantial responses and survival without chemotherapy, especially in newly diagnosed Ph+ ALL. The lower survival reported in refractory cases underscores that outcomes may differ by disease setting. These findings provide a rationale for further evaluation but do not establish comparative benefit or long-term effectiveness.
What to keep in mind
The meta-analysis included 8 studies, and the authors state that larger randomized trials are needed to confirm long-term outcomes.